Suppression of SARS-CoV entry by peptides corresponding to heptad regions on spike glycoprotein
Open accessThe DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
Heptad repeat regions (HR1 and HR2) are highly conserved sequences located in the glycoproteins of enveloped viruses. They form a six-helix bundle structure and are important in the process of virus fusion. Peptides derived from the HR regions of some viruses have been shown to inhibit the entry of these viruses. SARS-CoV was also predicted to have HR1 and HR2 regions in the S2 protein. Based on this prediction, we designed 25 peptides and screened them using a HIV-luc/SARS pseudotyped virus assay. Two peptides, HR1-1 and HR2-18, were identified as potential inhibitors, with EC50 values of 0.14 and 1.19 μM, respectively. The inhibitory effects of these peptides were validated by the wild-type SARS-CoV assay. HR1-1 and HR2-18 can serve as functional probes for dissecting the fusion mechanism of SARS-CoV and also provide the potential of further identifying potent inhibitors for SARS-CoV entry.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus
Li, W., Moore, M. J., Vasilieva, N., Sui, J., Wong, S. K., Berne, M. A., Somasundaran, M., Sullivan, J. L., Luzuriaga, K., Greenough, T. C., et al. (2003) · Nature · doi:10.1038/nature02145 · Cited by 5,923 · cited 4×
“Despite the early success in SARS-CoV genome sequencing [5] and later the identification of receptor ACE2 [6,7], neither efficacious therapies nor preventive treatments have yet been available.”
BackgroundInfluentialIdentification of a novel coronavirus in patients with severe acute respiratory syndrome
Drosten, C., Günther, S., Preiser, W., van der Werf, S., Brodt, H.-R., Becker, S., Rabenau, H., Panning, M., Kolesnikova, L., Fouchier, R. A. M., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030747 · Cited by 4,574
Bosch, B. J., van der Zee, R., de Haan, C. A. M., & Rottier, P. J. M. (2003) · Journal of Virology · doi:10.1128/jvi.77.16.8801-8811.2003 · Cited by 1,489
Cited by
Coronaviruses — drug discovery and therapeutic options
Zumla, A., Chan, J. F. W., Azhar, E. I., Hui, D. S. C., & Yuen, K.-Y. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2015.37 · Cited by 1,707
The spike protein of SARS-CoV — a target for vaccine and therapeutic development
Du, L., He, Y., Zhou, Y., Liu, S., Zheng, B.-J., & Jiang, S. (2009) · Nature Reviews Microbiology · doi:10.1038/nrmicro2090 · Cited by 1,661
The Severe Acute Respiratory Syndrome
Peiris, J. S. M., Yuen, K. Y., Osterhaus, A. D. M. E., & Stöhr, K. (2003) · New England Journal of Medicine · doi:10.1056/nejmra032498 · Cited by 1,346
From SARS to MERS, Thrusting Coronaviruses into the Spotlight
Song, Z., Xu, Y., Bao, L., Zhang, L., Yu, P., Qu, Y., Zhu, H., Zhao, W., Han, Y., & Qin, C. (2019) · Viruses · doi:10.3390/v11010059 · Cited by 1,265
Severe acute respiratory syndrome coronavirus as an agent of emerging and reemerging infection
Cheng, V. C. C., Lau, S. K. P., Woo, P. C. Y., & Yuen, K. Y. (2007) · Clinical Microbiology Reviews · doi:10.1128/cmr.00023-07 · Cited by 1,192
Coronavirus membrane fusion mechanism offers a potential target for antiviral development
Tang, T., Bidon, M., Jaimes, J. A., Whittaker, G. R., & Daniel, S. (2020) · Antiviral Research · doi:10.1016/j.antiviral.2020.104792 · Cited by 761
Yuan, Y., Cao, D., Zhang, Y., Ma, J., Qi, J., Wang, Q., Lu, G., Wu, Y., Yan, J., Shi, Y., et al. (2017) · Nature Communications · doi:10.1038/ncomms15092 · Cited by 760
Antimicrobial peptides (AMPs): A promising class of antimicrobial compounds
Erdem Büyükkiraz, M., & Kesmen, Z. (2022) · Journal of Applied Microbiology · doi:10.1111/jam.15314 · Cited by 454
Molecular Interactions in the Assembly of Coronaviruses
de Haan, C. A. M., & Rottier, P. J. M. (2005) · Advances in Virus Research · doi:10.1016/s0065-3527(05)64006-7 · Cited by 408
Crystal Structure of Severe Acute Respiratory Syndrome Coronavirus Spike Protein Fusion Core
Xu, Y., Lou, Z., Liu, Y., Pang, H., Tien, P., Gao, G. F., & Rao, Z. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m408782200 · Cited by 252
Follis, K. E., York, J., & Nunberg, J. H. (2006) · Virology · doi:10.1016/j.virol.2006.02.003 · Cited by 231
“To determine whether proteolytic cleavage of the normally uncleaved SARS-CoV S glycoprotein affects virion infectivity, we generated pseudotyped retroviral virions bearing the wild-type and HTVR SARSCoV glycoproteins (Moore et al., 2004; Simmons et al., 2004; Yang et al., 2004; Yuan et al., 2004).”
BackgroundCannabinoids Block Cellular Entry of SARS-CoV-2 and the Emerging Variants
van Breemen, R. B., Muchiri, R. N., Bates, T. A., Weinstein, J. B., Leier, H. C., Farley, S., & Tafesse, F. G. (2022) · Journal of Natural Products · doi:10.1021/acs.jnatprod.1c00946 · Cited by 135
Metadata
- Authors
- Yuan, K., Yi, L., Chen, J., Qu, X., Qing, T., Rao, X., Jiang, P., Hu, J., Xiong, Z., Nie, Y., Shi, X., Wang, W., Ling, C., Yin, X., Fan, K., Lai, L., Ding, M., & Deng, H.
- Venue
- Biochemical and Biophysical Research Communications
- Publisher
- Elsevier BV
- Published
- 2004-07
- Volume
- 319
- Issue
- 3
- Pages
- 746-752
- ISSN
- 0006-291X (ISSN-L)
- OpenAlex
- W2107860569
- Cited by
- 109
- References
- 3
- FWCI
- 7.62
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.